Patients who were older at MS onset had an increased risk for progression independent of disease activity.
Progression independent of relapse activity begins in early multiple sclerosis (MS) but becomes more frequent in secondary progressive MS (NEJM JW Neurol 2023 and JAMA Neurol 2023; 80:151). To evaluate early disease characteristics soon after a first demyelinating event, investigators conducted this retrospective review of clinical outcomes for 1170 patients split into three groups by age at first episode of demyelination: 18–29 years, 30–39 years, and 40–50 years.
Compared with the 18- to 29-year-old group, significantly greater proportions of the 40- to 50-year-old group demonstrated relapse-associated worsening (34% vs. 25%), confirmed disability accumulation (hazard ratio, 1.5), progression independent of relapse activity (HR, 2.5), and …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)